ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California. Show more

12526 High Bluff Drive, San Diego, CA, 92130, United States

Biotechnology

Healthcare

Market Cap

59.22M

52 Wk Range

$3.94 - $18.00

Previous Close

$5.25

Open

$5.29

Volume

5,883

Day Range

$5.29 - $5.75

Enterprise Value

-55.58M

Cash

117.2M

Avg Qtr Burn

-14.8M

Insider Ownership

14.96%

Institutional Own.

55.48%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IMG-007 (OX40 Antagonist) Details Moderate-To-Severe Atopic Dermatitis	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMG-007 (OX40 Antagonist) Details Alopecia Areata	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.